One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease
Daniel O’Hair(UPMC Health System), George Petrossian, Daniel Watson(Riverside Methodist Hospital), Neal S. Kleiman(Houston Methodist), Tanvir Bajwa(Aurora Health Care), Robert F. Hebeler(Baylor University Medical Center), Stanley Chetcuti(University of Michigan), Jeffrey J. Popma(Cardiovascular Research Foundation), Michael J. Reardon(Houston Methodist), David Adams(Mount Sinai Health System), Shuzhen Li(Hubei University of Medicine), G. Michael Deeb(University of Michigan), Robert Stoler(Baylor University Medical Center), Steven J. Yakubov(OhioHealth), Mubashir Mumtaz(University of Pittsburgh Medical Center), Brijeshwar Maini(Florida Atlantic University)
Cited by 12
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
|New England Journal of Medicine|2010|3k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk Patients
|New England Journal of Medicine|2004|2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k